Methylxanthine use for apnea of prematurity among an international cohort of neonatologists

Journal of Neonatal-Perinatal Medicine

Volumn 6, Issue 3, 2013, Pages 251-256

  Abu Jawdeh, E G ^a,b   O'Riordan, M ^a   Limrungsikul, A ^c   Bandyopadhyay, A ^a,b   Argus, B M ^d   Nakad, P E ^e   Supapannachart, S ^c   Yunis, K A ^e   Davis, P G ^d   Martin, R J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Caffeine; international health; practice variation; premature infants; questionnaire; survey

Indexed keywords

AMINOPHYLLINE; CAFFEINE; METHYLXANTHINE; THEOPHYLLINE;

ARTICLE; ARTIFICIAL VENTILATION; AUSTRALIA; CROSS-SECTIONAL STUDY; FEMALE; HOME MONITORING; HUMAN; LEBANON; MAJOR CLINICAL STUDY; MALE; NEONATOLOGIST; NEWBORN; NEWBORN APNEA; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; THAILAND; UNITED STATES;

CAFFEINE; INTERNATIONAL HEALTH; PRACTICE VARIATION; PREMATURE INFANTS; QUESTIONNAIRE; SURVEY;

APNEA; AUSTRALIA; CAFFEINE; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LEBANON; MALE; NEONATOLOGY; QUESTIONNAIRES; THAILAND; UNITED STATES; XANTHINES;

EID: 84887978694     PISSN: 19345798     EISSN: 18784429     Source Type: Journal    
DOI: 10.3233/NPM-1371013     Document Type: Article

References (15)

1. Eichenwald EC, Aina A, Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Pediatrics 1997;100:354-9.
2. Abu-Shaweesh JM, Martin RJ. Neonatal apnea: What's new? Pediatr Pulmonol 2008;43:937-44.
3. Martin RJ, Wang K, Koroglu O, Di Fiore J, Kc P. Intermittent hypoxic episodes in preterm infants: Do they matter? Neonatology 2011;100:303-10.
4. Pillekamp F, Hermann C, Keller T, von Gontard A, Kribs A, Roth B. Factors influencing apnea and bradycardia of prematurity-implications for neurodevelopment. Neonatology 2007;91:155-61.
5. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354: 2112-21.
6. Uauy R, Shapiro DL, Smith B, Warshaw JB. Treatment of severe apnea in prematures with orally administered theophylline. Pediatrics 1975;55:595-8.
7. Aranda JV, GormanW, Bergsteinsson H, Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr 1977;90:467-72.
8. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007;357:1893-902.
9. Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012;307:275-82.
10. Pesce AJ, Rashkin M, Kotagal U. Standards of laboratory practice: Theophylline and caffeine monitoring. National academy of clinical biochemistry. Clin Chem 1998;44(5): 1124-8.
11. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: An unnecessary exercise? Pediatrics 2007;119:936-40.
12. Darnall RA, Kattwinkel J, Nattie C, Robinson M. Margin of safety for discharge after apnea in preterm infants. Pediatrics 1997;100:795-801.
13. Eichenwald EC, Blackwell M, Lloyd JS, Tran T, Wilker RE, Richardson DK. Inter-neonatal intensive care unit variation in discharge timing: Influence of apnea and feeding management. Pediatrics 2001;108:928-33.
14. Ducrocq S, Biran-MucignatV, Boelle PY, Lebas F, Baudon JJ, Gold F. [Apnea of prematurity: Risk factors and ambulatory treatment with caffeine citrate]. Arch Pediatr 2006;13:1299-304. Apnees tardives du premature: Facteurs de risque, traitement ambulatoire par citrate de cafeine.
15. Rothenberg R, Koplan JP, Cutler C, Hillman AL. Changing pediatric practice in a changing medical environment: Factors that influence what physicians do. Pediatr Ann 1998;27:241-50.